Description
A p38α MAP kinase inhibitor (IC50 = 13 nM); inhibits TNF-α production in PBMCs (IC50 = 50 nM); reduces LPS-induced TNF-α production up to 89% in mice at 5 mg/kg; reduces paw swelling in a rat adjuvant arthritis model when administered once per day (1, 10, or 100 mg/kg) or twice per day (1 or 5 mg/kg),
Formal name: 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propyl-pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide
Synonyms:
Molecular weight: 406.5
CAS: 623152-17-0
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Kinase Inhibitors|p38 MAPK||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Immunology & Inflammation|Autoimmunity|Rheumatoid Arthritis||Research Area|Immunology & Inflammation|Innate Immunity
